Review Article

Comparison between Arm Port and Chest Port for Optimal Vascular Access Port in Patients with Breast Cancer: A Systematic Review and Meta-Analysis

Ye Liu, Li-li Li, Lei Xu, Dong-dong Feng, Yu Cao, Xiao-yun Mao, Jin Zheng, Feng Jin, and Bo Chen

Department of Breast Surgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, China
Department of Urology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, China

Correspondence should be addressed to Bo Chen; bo.chen@dr.com

Received 17 September 2019; Accepted 15 October 2019; Published 13 February 2020

Guest Editor: Kang Purum

Copyright © 2020 Ye Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objectives. This meta-analysis was conducted to compare the complication rates between arm and chest ports in patients with breast cancer. Design and Data Sources. PubMed, Embase, Cochrane library, Chinese National Knowledge Infrastructure (CNKI), and Wanfang database were used to perform a systematic review and meta-analysis of publications published from the inception of the database to 11, October 2019. Our search generated a total of 22 articles published from 2011 to 2019, including 6 comparative studies and 16 single-arm articles, involving 4131 cases and 5272 controls. Single-arm studies combined with comparative studies were also pooled and analyzed. Finally, subgroup analysis was performed to compare the rates of infection and thrombosis between these two ports. Eligibility Criteria. Included articles were research studies comparing complication rates of arm ports with chest ports in patients with breast cancer. Any review or meta-analysis article would be removed. Data Extraction and Synthesis. Demographic data and information for the following analysis were extracted. DerSimonian and Laird random effect meta-analysis was conducted to analyze comparative studies while Begg’s and Egger’s tests were used for assessment of publication bias. Meta-regression analysis was performed to explain the sources of heterogeneity. Results. There was no difference in the risk of overall complications between arm and chest ports for comparative studies (P = 0.083). While results of pooled comparative and single-arm studies indicated that arm port would increase the overall complication risks with RR of 2.64, results of the subgroup analysis showed that there was no difference in the risk of catheter-related infection between these two ports. However, arm port might be associated with the higher thrombosis rates compared with chest port according to the results of the analysis for only comparative studies (RR = 2.23, P = 0.041) as well as pooled comparative and single-arm studies (RR = 1.21, P = 0.029). Conclusions. This study indicated that the arm port might increase the risk of overall complication risks as well as the risk of catheter-related thrombosis compared with the chest port. However, these reported findings still need to be verified by large randomized clinical trials.

1. Introduction

Totally implanted venous access port (TIVAP) has been established as an effective and safe procedure for cancer patients, which could be applied to chemotherapy infusion, blood sampling, as well as nutrition supply [1, 2]. TIVAPs have manifested evident superiority with fewer complications and more convenient catheter management compared with peripherally inserted central catheter or any other externally tunneled catheter [3]. In recent years, TIVAPs have been widely used in patients with malignancies needing to receive a long-term catheterization. In general, TIVAPs are inserted into the chest through a subclavian vein or jugular vein under the guidance of ultrasound or surgery. However, with high pneumothorax rate and poor aesthetic appearance, the chest port is being replaced by the peripheral arm port, which is mainly inserted through the basilic vein, and less often the brachial vein. Arm ports are usually implanted via
peripheral arm veins at the bedside without using an operating room. Consequently, this access method is safer, has a lower infection rate, is more cost-effective, and has less risk of pneumothorax when compared with the chest ports.

Different implantation methods may lead to different risks of complication occurrence between arm ports and chest ports, which may have a vital role in the catheters span and the safety as well as the quality of life in cancer patients. Based on the guidelines for the prevention of catheter-related infections reported by O’Grady et al., catheter-infections are the most common ones among all catheter-related complications [4]. In addition, venous thrombosis is another catheter-related complication that should not be neglected. Although the arm port contains an obvious superiority over the chest port due to the lower risk of pneumothorax during the perioperative period, it is still controversial due to the incidence rate of late complications. This especially relates to the risk of thrombosis occurrence due to the long length of arm port catheters and the higher movement of the arm part. Previous studies have reported no significant differences in catheter durability and complication risk between chest ports and arm ports [5]; however, these conclusions were not consistent across all studies [6]. Patients can choose between these two venous ports; however, the risk of complications incidence must be considered before implantation. Nonetheless, currently there are no systematic studies concerning the differences of complication rates between these two port systems in patients with breast cancers.

The aim of this meta-analysis was to systematically compare the complication rates of arm ports with chest ports in patients with breast cancer so as to fill in the gaps and provide guidance that would aid decision-making for access ports selection.

2. Materials and Methods

2.1. Search Strategy. This analysis was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement and checklist (PRISMA). We searched PubMed, Embase, Cochrane Library, CNKI, and Wanfang database for relevant publications. The search strategy was as follows: (implanted venous access ports OR peripheral ports OR forearm ports OR upper arm ports OR arm ports OR chest ports OR ports) AND (breast cancer OR mammory cancer), updated to October 11, 2019. Reference lists of reviews and meta-analysis articles were also searched for potentially relevant articles.

2.2. Literature Selection. Literature was selected based on a series of inclusion and exclusion criteria. Inclusion criteria were the following: (1) Participants enrolled in the study were patients with breast cancer; (2) the type of catheter studied was arm port or chest port; (3) the number of total participants and the number of complication cases can be calculated or extracted from papers. The exclusion criteria were as follows: (1) Unrelated publications, reviews, and meta-analysis articles; (2) articles without complete information.

2.3. Data Extraction and Quality Assessment. Data were extracted from the enrolled publications by two authors (Ye Liu and Lili Li) independently as listed: the first author, publication country and year, participants’ age, sample size, the type and number of complication cases, the mean duration of catheter, and the types of the study design. The quality of the included articles was evaluated based on the National Institutes of Health Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies [7].

2.4. Statistical Analysis. Two different sets of meta-analytical methods were applied in this study. First, for studies that directly compared these two port types (hereinafter referred to as comparative studies), we performed the DerSimonian and Laird random effects model (REM) meta-analysis. The pooled relative risk (RR) with its 95% CI was evaluated. Begg’s and Egger’s tests were used to evaluate the possibility of publication bias with P value less than 0.05. Second, both single-arm and comparative studies were pooled and synthesized to analyze the difference in complication rates between these two ports. For both analysis models, the heterogeneity among the selected articles was assessed by Q test and I² value [8]. I² ≥ 50% or P value for the Q test less than 0.05 indicated that there was significant heterogeneity among these studies, and then a meta-regression analysis (grouped by age: <50, ≥50 and not accessible; gender: only female, female and male as well as not accessible; ethnicity: Asian and Caucasian; catheter size: <5F, ≥ 5F and not accessible; quality of the study: fair and good) was used to identify the potential sources of the heterogeneity. The comparison between single-arm studies and single chest studies was conducted by SPSS 22.0 (SPSS Inc., Chicago, IL, USA) and all other statistical analyses were performed by STATA 11.0 (STATA-Corp, College Station, TX, USA) software; the statistical significance was set as P < 0.05.

3. Results

3.1. Publication Search and Studies’ Characteristics. As shown in Figure 1, based on the primary protocol of the publication search, 1732 eligible articles were enrolled, of which 224 articles were excluded since they were reviews, meta-analysis articles, letters, and conference papers. Other 27 duplicated articles and 1424 unrelated articles were also excluded, resulting in 57 papers with full texts. Further, another 35 articles were removed due to missing data. Ultimately, 22 articles published from 2011 to 2019 including 6 comparative studies and 16 single-arm articles (3 articles for arm port and 13 articles for chest port), involving in 4131 cases and 5272 controls [9-30] were included in the study. The main characteristics of these 22 studies are listed in Table 1 and their quality resulted to be generally good as shown in Table 1 and supplementary file S1.

3.2. Pooled Analysis

3.2.1. Meta-Analysis of Comparative Studies. Fixed-effect model was performed since no significant heterogeneity was
observed among these six comparative studies ($I^2 = 48.6\%$, $P = 0.083$). The pooled RR was 1.01 (95% CI: 0.77–1.34) with $Z = 0.09$ and $P = 0.928$ for arm port versus chest port as shown in Figure 2, which indicated that arm port would not increase the risk of complications compared with the chest port. Publication bias was estimated under a random effect model and no obvious publication bias was found among these studies with $P$ value of the Egger’s test equal to 0.677 (Figure 3).

3.2.2. Meta-Analysis Combined Single-Arm and Comparative Studies. The pooled absolute risk (AR) and its 95% CI were 0.06 (0.05, 0.08) for arm port (Figure 4) and 0.09 (0.06, 0.12) for chest port (Figure 5), respectively, combining comparative studies and single-arm studies. The pooled RR and its 95% CI were 2.64 and 2.28–3.07, respectively, indicating a 2.64-fold complication risk of arm port compared with chest port with $P < 0.001$. RD was -0.03 with 95% CI equaling to -0.07–0.02. Since there was high heterogeneity among the studies for chest port, a meta-regression was conducted and no sources of the heterogeneity were found.

In brief, the meta-analysis for the six comparative studies demonstrated that the arm port did not decrease the complication risk compared with the chest port, while a higher risk was found for arm port when combined with the comparative studies and single-arm studies.

3.3. Subgroup Analysis

3.3.1. The Rate of Catheter-Related Infection. A total of 18 studies reported the incidence rate of catheter-related infection, of which 4 studies contained a direct comparison of arm port and chest port, whereas the remaining 14 articles were single-arm studies (Table 2). Since no significant heterogeneity existed among these 4 comparative studies ($I^2 = 0.0\%, P = 0.776$), a fixed-effect model was performed. The pooled RR was 0.58 (95% CI: 0.32–1.06) with $Z = 1.78$ and $P = 0.074$ for arm port versus chest port as shown in Supplementary Figure S1, indicating that there was no statistical difference of the complication risk between these two ports. The same result was obtained when summarizing and analyzing all of the studies (RR: 1.63; 95% CI: 0.97–2.75; $P = 0.064$).

3.3.2. Rate of Catheter-Related Thrombosis. A total of 19 studies reported the occurrence rate for catheter-related thrombosis, including 4 comparative studies and 15 single-arm studies (Table 2). Since no significant heterogeneity was found among these 4 comparative studies ($I^2 = 46.1\%, P = 0.135$), a fixed-effect model was performed. The pooled RR was 2.23 (95% CI: 1.04–4.79) with $Z = 2.05$ and $P = 0.041$ for arm port versus chest port, respectively, as shown in Supplementary Figure S2, which indicated that arm port would increase the risk of catheter thrombosis compared with chest port. Similar results were also obtained when enrolling the uncontrolled studies (RR: 1.21; 95% CI: 1.02–1.43; $P = 0.029$).

4. Discussion

TIVAP has a pivotal role in the treatment of patients with malignancy during chemotherapy with a lower rate of infectious complications than other externally tunneled catheters. Although chest ports inserted via internal jugular vein or subclavian vein are considered optimal, other insertion sites such as upper arm to decrease catheter-related complications have also been explored [31, 32]. Peripheral arm ports are comparable to the chest ports in arterial injury and have a prominent advantage of less pneumothorax [33]. Due to safety and cost-effectiveness related to bedside insertion, arm ports have been increasingly applied over recent years. Yet, a comparison of complication rates in patients with breast cancer between the arm port and chest port has not been fully taken into consideration. Thus in this study, we investigated whether arm port could decrease the risk of incidence and development of catheter-related complications in patients with breast cancer compared with chest ports. To our knowledge, this was the first systematic review and meta-analysis that assessed and compared the incidence rate of complications between arm ports and chest ports in patients with breast cancer.

Overall, in the present study, no difference of the complication risks was found between arm and chest ports from pooled estimates for comparative studies. However, results of pooled comparative and single-arm studies indicated that the overall complication risks for arm port were 2.64 times as much as risks for chest port, showing a prominent superiority for chest ports with less risks of complication incidence. In the subgroup analysis for catheter-related infection, arm port might not increase the infection risk compared with chest port. Besides catheter-related infection, catheter-related thrombosis is another particular concern because the use of TIVAPs in malignant
diseases has been related to a higher thrombosis incidence risk. According to the results of this meta-analysis, arm port might be associated with the higher thrombosis rates compared with chest port for comparative studies (RR = 2.23, P = 0.041) as well as pooled comparative and single-arm studies (RR = 1.21, P = 0.029). Above all, although there was no association between the placement of TIVAPs via arm port and the high risk of catheter-related infections, this venous port would increase the risks of overall complications as well as the catheter-related thrombosis compared with chest port. Therefore, it is suggested that chest port should be taken as the primary way to construct a totally implanted venous access port for patients with breast cancer to reduce the risk of catheter-

| Study     | Year | Country | Age | Sex | Case (arm) | Control (chest) | Mean duration (days) | Catheter size | Quality of studies |
|-----------|------|---------|-----|-----|------------|-----------------|----------------------|---------------|-------------------|
| Marcy     | 2005 | France  | 55.7| F   | 100        | 100             | 100                  | 16            | 228               | 7F               | Good              |
| Peynircioglu | 2007 | Turkey  | 48.3| F   | 1          | 15              | 1                    | NA            | 462               | 5.8F/6.8F        | Fair              |
| Dong      | 2016 | China   | NA  | F   | 810        | 995             | 52                   | NA            | NA                | NA               | Good              |
| Tippit    | 2018 | USA     | 55  | F   | 147        | 150             | 4                    | 669.4         | 52.3              | 5.5F             | Good              |
| Yang      | 2018 | Korea   | 51.6| F   | 176        | 55              | 9                    | 175.2         | 202.4             | 5F/8F            | Good              |
| Wang      | 2019 | China   | 52.3| F   | 95         | 76              | 6                    | 176           | 109               | 4.8F/6.6F        | Good              |
| Xu        | 2017 | China   | 50.6| F   | 25         | 56              | NA                   | NA            | NA                | NA               | Fair              |
| Decousus  | 2018 | France  | 63  | NA  | 2664       | 275             | NA                   | NA            | NA                | NA               | Fair              |
| Awan      | 2019 | Canada  | NA  | F   | 73         | 4               | NA                   | NA            | NA                | NA               | Good              |
| Pardo     | 2011 | USA     | 52  | NA  | 45         | 6               | NA                   | NA            | NA                | NA               | Fair              |
| Teichgraber | 2013 | Germany | NA  | NA  | 121        | 223             | NA                   | NA            | NA                | NA               | Fair              |
| Piran     | 2014 | Canada  | 58.0 | F/M | 183        | 360             | 7                    | 6-8F          | Good              |
| Song      | 2015 | Korea   | 51.4| F   | 191        | 368             | 15                   | 8F            | Good              |
| Liu       | 2017 | China   | 48.7| F   | 755        | 147.3           | 225                  | 7-8F          | Good              |
| Mao       | 2017 | China   | 46.0 | F/M | 158        | 245.2           | 10                   | 7-8F          | Good              |
| Mo        | 2017 | China   | NA  | F/M | 658        | 147.3           | 12                   | 7-8F          | Good              |
| LeVasseur | 2018 | Canada  | 55  | NA  | 62         | 334.6           | 14                   | 6.5-8F        | Good              |
| Song      | 2018 | Korea   | 51.5| F   | 209        | 396             | 16                   | NA            | 8F                | Fair              |
| Makary    | 2018 | USA     | 53.1| F   | 396        | NA              | 16                   | NA            | 8F                | Fair              |
| Erhancil  | 2019 | Turkey  | 54  | F   | 68         | 969.8           | 4                    | NA            | Good              |
| Isom      | 2019 | USA     | 52.9| F   | 581        | 581             | 36                   | NA            | NA                | Fair              |
| Zhang     | 2019 | China   | 52  | NA  | 110        | 110             | 11                   | NA            | NA                | Fair              |

Note. N: the number of total participants; m: the number of all patients who suffered from complications; * meant the age was median while others were mean; 1: catheter size for arm port; 2: catheter size for chest port; NA: not accessible.

Figure 2: Forest plot of comparative studies’ meta-analysis for the association between arm or chest ports and the risk of complication incidence. Each study was shown by a square with its 95% confidence interval shown by the error bars.
related thrombosis as well as other complications except for the infections.

The present study has some limitations. First, this study might suffer from patient selection bias since most of the enrolled studies were retrospective designs. Furthermore, most of the articles were uncontrolled studies, which might also affect the quality of the pooled estimates. Therefore, prospective randomized controlled studies are warranted to confirm our results that were attained through pooled analysis of 22 articles conducted in varied settings, countries as well as protocols.

5. Conclusion

Overall, there was no association between the arm port and the high risk of catheter-related infections; this venous port would increase the risks of overall complications as well as the catheter-related thrombosis compared with chest port. We considered the chest port might be more suitable for patients with breast cancers. However, these results still need to be verified by future studies.

Additional Points

Strengths and Limitations of This Study. (1) This meta-analysis study is significant in terms of the arm port and chest port in patients with breast cancer. (2) It provides guidance for decision-making of access ports selection. (3) Most of the enrolled studies were of retrospective design. (4) There was high heterogeneity among different studies.

Conflicts of Interest

The authors declare that they have no conflicts of interest.
Authors’ Contributions

All of the authors made a substantial contribution to this work. YL, YC, XM, JZ, FJ, and BC contributed to the conception and design of the review. YL and BC read and screened abstracts and titles of potentially relevant studies. YL, LL, LX, and DF read the retained papers and were responsible for extracting data and rating their quality independently. YL and BC drafted the paper with all the authors critically reviewing it and suggesting amendments prior to submission. All the authors had access to all the data in the study and take full responsibility for the integrity of the reported findings.

Acknowledgments

This study was supported by the National Key Research and Development Program of China (Grant no. 2017YFC0114205), the First Affiliated Hospital of China Medical University Nursing Department Fund (Grant No. HLB-2019-05), Science and Technology Plan Project of Liaoning Province (Grant no. 2013225585), and China Postdoctoral Science Foundation (Grant no. 2017M621178).

Supplementary Materials

Figure S1: forest plots of comparative studies’ meta-analysis for the association between arm or chest ports and the risk of catheter-related infections. Each study is shown by a square with its 95% Confidence interval shown by the error bars. Figure S2: forest plots of comparative studies’ meta-analysis for the association between arm or chest ports and the risk of catheter-related thrombosis. Each study is shown by a square with its 95% Confidence interval shown by the error bars. The Quality Assessment for the Enrolled Studies was

Table 2: The subgroup analysis for the selected studies.

| Subgroups        | No. of studies | AR [95%CI]         | RR [95%CI]         | RD [95%CI]         | P      |
|------------------|----------------|--------------------|--------------------|--------------------|--------|
| Infection        |                |                    |                    |                    |        |
| Comparative      | 4              | 0.027[0.003–0.051] | 0.58[0.32–1.055]   | 0.074              |        |
| Arm              | 5              | 0.007[0.002–0.011] | 1.63[0.97–2.75]    | 0.02[−0.008–0.049] | 0.064  |
| Chest            | 13             |                    |                    |                    |        |
| Thrombosis       |                |                    |                    |                    |        |
| Comparative      | 4              | 2.23[1.04–4.79]    | 0.045[−0.002–0.093] | 0.041              |        |
| Arm              | 6              | 1.21[1.02–1.43]    | 0.003[−0.059–0.065] | 0.029              |        |
| Chest            | 13             | 0.042[0.028–0.057] |                    |                    |        |

AR: absolute risk; RR: risk ratio; RD: risk difference.
References

[1] R. Biffi, G. Martinelli, S. Pozzi et al., “Totally implantable central venous access ports for high-dose chemotherapy administration and autologous stem cell transplantation: analysis of overall and septic complications in 68 cases using a single type of device,” Bone Marrow Transplantation, vol. 24, no. 1, pp. 89–93, 1999.

[2] R. Biffi, S. Pozzi, A. Agazzi et al., “Use of totally implantable central venous access ports for high-dose chemotherapy and peripheral blood stem cell transplantation: results of a monocentre series of 376 patients,” Annals of Oncology, vol. 15, no. 2, pp. 296–300, 2004.

[3] A. Robinson, O. Souded, A. B. Bota et al., “Optimal vascular access strategies for patients receiving chemotherapy for early-stage breast cancer: a systematic review,” Breast Cancer Research and Treatment, vol. 171, no. 3, pp. 607–620, 2018.

[4] N. P. O’Grady, M. Alexander, L. A. Burns et al., “Guidelines for the prevention of intravascular catheter-related infections,” American Journal of Infection Control, vol. 39, no. 4, pp. S1–S34, 2011.

[5] A. Weickhardt, T. Joseph, S. Shea et al., “Comparison of radiologically inserted arm portversus surgically placed chest ports for chemotherapy,” Asia-Pacific Journal of Clinical Oncology, vol. 5, no. 3, pp. 181–186, 2009.

[6] P.-Y. Marcy, E. Chamorey, N. Amoretti et al., “A comparison between distal and proximal port device insertion in head and neck cancer,” European Journal of Surgical Oncology (EJSO), vol. 34, no. 11, pp. 1262–1269, 2008.

[7] National Heart Lung and Blood Institute, “Study quality assessment tools,” 2018, https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools.

[8] J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” BMJ, vol. 327, no. 7414, pp. 557–560, 2003.

[9] S.-S. Yang and M. S. Ahn, “A comparison between upper arm and chest for optimal site of totally implanted venous access ports in patients with female breast cancer,” Annals of Vascular Surgery, vol. 50, pp. 128–134, 2018.

[10] D. Tippit, E. Siegel, D. Ochoa et al., “Upper-extremity deep vein thrombosis in patients with breast cancer with chest versus arm central venous port catheters,” Breast Cancer: Basic and Clinical Research, vol. 12, 2018.

[11] M. S. Makary, A. Lionberg, M. Khayat et al., “Advanced stage breast cancer is associated with catheter-tip thrombus formation following implantable central venous port placement,” Phlebology: The Journal of Venous Disease, vol. 34, no. 2, pp. 107–114, 2018.

[12] N. LeVasseur, C. Stober, K. Daigle et al., “Optimizing vascular access for patients receiving intravenous systemic therapy for early-stage breast cancer–a survey of oncology nurses and physicians,” Current Oncology, vol. 25, no. 4, pp. e305–e10, 2018.

[13] H. P. Xu, S. Wang, Y. Wang, D. D. Liu, and W. Han, “Application of arm infusion port in breast cancer patients with chemotherapy and the practice of remote management,” Chinese Journal of Practical Nursing, vol. 33, no. 13, pp. 1009–1012, 2017.

[14] X. F. Mo, D. Y. Ji, and S. F. Wu, “Nursing of complications of breast cancer patients caused by the implantable venous access port,” Chinese Clinical Nursing, vol. 9, no. 6, pp. 473–474, 2017.

[15] L. Mao, F. F. Liu, G. Yin, and X. D. Huang, “The application of implantable venous access ports in management of postoperative breast cancer patients,” Anhui Medical and Pharmaceutical Journal, vol. 21, no. 4, pp. 683–686, 2017.

[16] H. Liu, G. Shi, L. Xing, and F. Luo, “Related complications of implantable venous access port,” Journal of Regional Anatomy and Operative Surgery, vol. 26, no. 9, pp. 648–651, 2017.

[17] M. G. Song, T.-S. Seo, E. Y. Kang, H. S. Yong, J. H. Seo, and Y. Y. Choi, “Innominate vein stenosis in breast cancer patients after totally implantable venous access port placement,” The Journal of Vascular Access, vol. 16, no. 4, pp. 315–320, 2015.

[18] U. Teichgräber, S. Nagel, and S. Kausche, “Evaluation of correlations between underlying disease and port complications,” RöFo-Fortschrchte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, vol. 186, no. 5, pp. 496–500, 2014.

[19] S. Piran, V. Ngo, S. McDiarmid, G. Le Gal, W. Petricch, and M. Carrier, “Incidence and risk factors of symptomatic venous thromboembolism related to implanted ports in cancer patients,” Thrombosis Research, vol. 133, no. 1, pp. 30–33, 2014.

[20] I. Pardo, E. L. Rager, M. W. Bowling, A. Fajardo, S. Clare, and R. Goulet Jr., “Central venous port placement: a comparison of axillary versus anterior chest wall placement,” Annals of Surgical Oncology, vol. 18, no. 2, pp. 468–471, 2011.

[21] B. Peynircioglu, E. B. Arslan, B. E. Gil et al., “Subcutaneous venous port implantation in patients with bilateral breast surgery,” CardioVascular and Interventional Radiology, vol. 30, no. 3, pp. 405–409, 2007.

[22] P.-Y. Marcy, N. Magné, P. Castadot et al., “Radiological and surgical placement of port devices: a 4-year institutional analysis of procedure performance, quality of life and cost in breast cancer patients,” Breast Cancer Research and Treatment, vol. 92, no. 1, pp. 61–67, 2005.

[23] B. E. Gil, O. Ocak, F. G. Eldem, B. Peynircioglu, and F. Balkanci, “Trapezius port placement in patients with breast cancer: long-term follow-up and quality-of-life assessment,” Journal of Vascular and Interventional Radiology, vol. 30, no. 1, pp. 69–73, 2019.

[24] H. Decousus, A. Bourmaud, P. Fournel et al., “Cancer-associated thrombosis in patients with implanted ports: a prospective multicenter French cohort study (ONCOCIP),” Blood, vol. 132, no. 7, pp. 707–716, 2018.

[25] M. G. Song, T.-S. Seo, Y. H. Kim et al., “Effect of catheter diameter on left innominate vein in breast cancer patients after totally implantable venous access port placement,” The Journal of Vascular Access, vol. 19, no. 6, pp. 615–619, 2018.

[26] C. Isom, P. Bream Jr., K. Gallagher, S. Walia, R. Ahmed, and R. Kaufmann, “Placement of subcutaneous central venous ports in breast cancer patients: does side matter?” Journal of Surgical Research, vol. 244, pp. 296–301, 2019.

[27] P. Zhang, J. Du, C. Fan et al., “Utility of totally implantable venous access ports in patients with breast cancer,” The Breast Journal, pp. 1-2, 2019.

[28] X. Y. Wang, F. Liu, X. Zhao, and Q. Liu, “A comparative study on the application of central venous infusion port inserted at different sites in patients with breast cancer undergoing chemotherapy,” Chinese Journal of Nursing, vol. 54, no. 6, pp. 917–921, 2019.
[29] J. Dong, R. Zhuo, Y. J. Zhang, X. F. Shi, and S. Lin, “Clinical research of two implanting methods of chemotherapy port in cephalic vein and subclavian vein,” in Proceedings of the 14th Symposium on Breast Diseases of Traditional Chinese Medicine and Integrated Chinese and Western Medicine 2016, pp. 421–426, Guangzhou, China, 2016.

[30] A. A. Awan, B. Basulaiman, A. Robinson et al., “A prospective, multicentre, randomized trial comparing vascular access strategies for patients receiving non-trastuzumab containing chemotherapy for early stage breast cancer,” Annals of Oncology, vol. 30, no. 3, pp. iii66–iii67, 2019.

[31] J. P. Goltz, C. Noack, B. Petritsch, J. Kirchner, D. Hahn, and R. Kickuth, “Totally implantable venous power ports of the forearm and the chest: initial clinical experience with port devices approved for high-pressure injections,” The British Journal of Radiology, vol. 85, no. 1019, pp. e966–e972, 2012.

[32] R. Biffi, F. Orsi, S. Pozzi et al., “Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial,” Annals of Oncology, vol. 20, no. 5, pp. 935–940, 2009.

[33] S. Wu, W. Li, Q. Zhang, S. Li, and L. Wang, “Comparison of complications between peripheral arm ports and central chest ports: a meta-analysis,” Journal of Advanced Nursing, vol. 74, no. 11, pp. 2484–2496, 2018.